An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates-Reference-Cited by-同舟云学术

An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates

Published:2015-06-25 Issue:11 Volume:32 Page:3584-3592
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Lansita Janice A.,Burke John M.,Apgar Joshua F.,Mounho-Zamora Barbara

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s11095-015-1742-y.pdf

Reference36 articles.

1. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies. 2013;2(1):113–29.

2. Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90.

3. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698–704.

4. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.

5. Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, Dunn KW. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell. 2008;19(12):5490–505.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation;Biochemical Pharmacology;2024-08

2. Preclinical Development of Antibody–Drug Conjugates;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

3. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability;Cancers;2023-01-24

4. Discovery and development of ADCs: obstacles and opportunities;Overcoming Obstacles in Drug Discovery and Development;2023

5. Protein Therapeutics;Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology;2023